Two Sigma Investments’s Acrivon Therapeutics ACRV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.16M Sell
564,956
-76,542
-12% -$146K ﹤0.01% 3480
2026
Q2
$1.14M Buy
641,498
+252,103
+65% +$428K ﹤0.01% 3508
2026
Q1
$541K Sell
389,395
-195,674
-33% -$341K ﹤0.01% 3690
2025
Q4
$1.41M Buy
585,069
+265,864
+83% +$578K ﹤0.01% 2701
2025
Q3
$578K Buy
319,205
+138,033
+76% +$194K ﹤0.01% 2918
2025
Q2
$216K Buy
+181,172
New +$249K ﹤0.01% 2892
2023
Q1
– Sell
-21,534
Closed -$248K – 2923
2022
Q4
$248K Buy
+21,534
New +$273K ﹤0.01% 2318

Other funds holding ACRV

Two Sigma Investments's ACRV Position: Q3 2026 in Review

Two Sigma Investments reduced its Acrivon Therapeutics (ACRV) stake by 12% in Q3 2026, selling an estimated $146K and leaving 564,956 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3480.

Two Sigma Investments first reported a position in ACRV in Q4 2022 and has held it in 7 quarters since. The position peaked at $1.41M in Q4 2025. 47 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Two Sigma Investments held 564,956 shares of Acrivon Therapeutics worth $1.16M as of Q3 2026.
  • Two Sigma Investments sold 76,542 Acrivon Therapeutics shares in Q3 2026, an estimated $146K.
  • Acrivon Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #3480 holding.
  • Two Sigma Investments first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • Two Sigma Investments's Acrivon Therapeutics position peaked at $1.41M in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.